Actavis Laboratories UT, Inc. was unable to show that patents licensed to Endo Pharmaceuticals Inc. covering its testosterone gel product Fortesta® were invalid as obvious in light of prior art, according to the U.S. Court of Appeals for the Federal Circuit. Therefore, a district court ruling finding that the patents were not obvious was affirmed (Endo Pharmaceuticals Inc. v. Actavis Laboratories UT, Inc., October 14, 2016, Taranto, R.).

A full summary of this case has been published on Kluwer IP Law.


_____________________________

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.


Kluwer IP Law

The 2021 Future Ready Lawyer survey showed that 81% of the law firms expect to view technology as an important investment in their future ability to thrive. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.

Kluwer IP Law
This page as PDF